IMI/REL FDC + PIP/TAZ FDC + Linezolid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hospital-Acquired Bacterial Pneumonia
Conditions
Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia
Trial Timeline
Sep 18, 2018 → Jul 12, 2022
NCT ID
NCT03583333About IMI/REL FDC + PIP/TAZ FDC + Linezolid
IMI/REL FDC + PIP/TAZ FDC + Linezolid is a phase 3 stage product being developed by Merck for Hospital-Acquired Bacterial Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT03583333. Target conditions include Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03583333 | Phase 3 | Completed |
Competing Products
2 competing products in Hospital-Acquired Bacterial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-8427 + Meropenem | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Zavicefta, Ceftazidime-Avibactam | Pfizer | Approved | 84 |